Alan M Birch

Summary

Affiliation: AstraZeneca R and D

Publications

  1. ncbi Development of potent, orally active 1-substituted-3,4-dihydro-2-quinolone glycogen phosphorylase inhibitors
    Alan M Birch
    AstraZeneca, Mereside, Alderley Park, Macclesfield, Cheshire SK10 4TG, UK
    Bioorg Med Chem Lett 17:394-9. 2007
  2. ncbi DGAT1 inhibitors as anti-obesity and anti-diabetic agents
    Alan M Birch
    AstraZeneca plc, Mereside, Alderley Park, Macclesfield, Cheshire, UK
    Curr Opin Drug Discov Devel 13:489-96. 2010
  3. ncbi Discovery of a potent, selective, and orally efficacious pyrimidinooxazinyl bicyclooctaneacetic acid diacylglycerol acyltransferase-1 inhibitor
    Alan M Birch
    AstraZeneca, Mereside, Alderley Park, Macclesfield, Cheshire SK10 4TG, United Kingdom
    J Med Chem 52:1558-68. 2009
  4. ncbi Identification, optimisation and in vivo evaluation of oxadiazole DGAT-1 inhibitors for the treatment of obesity and diabetes
    William McCoull
    Cardiovascular and Gastrointestinal Innovative Medicines Unit, AstraZeneca, Alderley Park, Macclesfield, Cheshire SK10 4TG, UK
    Bioorg Med Chem Lett 22:3873-8. 2012
  5. ncbi Use of small-molecule crystal structures to address solubility in a novel series of G protein coupled receptor 119 agonists: optimization of a lead and in vivo evaluation
    James S Scott
    Cardiovascular and Gastrointestinal Innovative Medicines Unit, AstraZeneca, Mereside, Alderley Park, Macclesfield, Cheshire SK10 4TG, United Kingdom
    J Med Chem 55:5361-79. 2012
  6. ncbi Novel thienopyrrole glycogen phosphorylase inhibitors: synthesis, in vitro SAR and crystallographic studies
    Paul R O Whittamore
    AstraZeneca, Alderley Park, Macclesfield, Cheshire, SK10 4TG, UK
    Bioorg Med Chem Lett 16:5567-71. 2006
  7. ncbi Matched molecular pair analysis of activity and properties of glycogen phosphorylase inhibitors
    Alan M Birch
    AstraZeneca, Mereside, Alderley Park, Macclesfield, Cheshire SK10 4TG, UK
    Bioorg Med Chem Lett 19:850-3. 2009
  8. ncbi Rationally designing safer anilines: the challenging case of 4-aminobiphenyls
    Alan M Birch
    AstraZeneca Pharmaceuticals, Mereside, Alderley Park, Macclesfield, SK10 4TG, UK
    J Med Chem 55:3923-33. 2012

Collaborators

  • Andrew G Leach
  • Andrew V Turnbull
  • Steven J Y Wang
  • Philip A Macfaul
  • Darren McKerrecher
  • Alleyn T Plowright
  • Nikos G Oikonomakos
  • Paul Schofield
  • Roger J Butlin
  • William McCoull
  • James S Scott
  • David P Whalley
  • Matthew S Addie
  • Paul R O Whittamore
  • Graeme C Moody
  • David Laber
  • Pernilla Sörme
  • Anders Broo
  • Anne Ertan
  • Kristin Goldberg
  • John Revill
  • Adrian Pickup
  • Ojvind Davidsson
  • Chris Sheldon
  • Linda K Buckett
  • Joanne Teague
  • Scott Boyd
  • J Matthew Wood
  • Steve Stokes
  • Julian A Hudson
  • Per H Svensson
  • Craig S Donald
  • Katy J Brocklehurst
  • Clive P Green
  • Susan Birtles
  • Thorsten Nowak
  • Martin J Packer
  • Chloe Jenner
  • Pablo Morentin Gutierrez
  • Stephen Chapman
  • Suzanne S Bowker
  • Paul D Kemmitt
  • Robert D M Davies
  • Sam D Groombridge
  • David S Clarke
  • Nicholas J Newcombe
  • Hayley S Brown
  • Michael Butters
  • Linda A Townsend
  • Stuart N L Bennett
  • Ludovic R Otterbein
  • Andrew D Morley
  • Paul M Murray
  • Andrew D Pannifer
  • Andy Stocker
  • Jennifer Whitehouse
  • Pawel S Siedlecki
  • Peter W Kenny
  • Melvyn J Taylor
  • Kristy Readman
  • Linda Godfrey
  • Jeremy S Parker

Detail Information

Publications8

  1. ncbi Development of potent, orally active 1-substituted-3,4-dihydro-2-quinolone glycogen phosphorylase inhibitors
    Alan M Birch
    AstraZeneca, Mereside, Alderley Park, Macclesfield, Cheshire SK10 4TG, UK
    Bioorg Med Chem Lett 17:394-9. 2007
    ..X-ray crystallographic data are presented, showing an unexpected variety of binding orientations at the dimer interface site...
  2. ncbi DGAT1 inhibitors as anti-obesity and anti-diabetic agents
    Alan M Birch
    AstraZeneca plc, Mereside, Alderley Park, Macclesfield, Cheshire, UK
    Curr Opin Drug Discov Devel 13:489-96. 2010
    ....
  3. ncbi Discovery of a potent, selective, and orally efficacious pyrimidinooxazinyl bicyclooctaneacetic acid diacylglycerol acyltransferase-1 inhibitor
    Alan M Birch
    AstraZeneca, Mereside, Alderley Park, Macclesfield, Cheshire SK10 4TG, United Kingdom
    J Med Chem 52:1558-68. 2009
    ....
  4. ncbi Identification, optimisation and in vivo evaluation of oxadiazole DGAT-1 inhibitors for the treatment of obesity and diabetes
    William McCoull
    Cardiovascular and Gastrointestinal Innovative Medicines Unit, AstraZeneca, Alderley Park, Macclesfield, Cheshire SK10 4TG, UK
    Bioorg Med Chem Lett 22:3873-8. 2012
    ..6 nM), good pharmacokinetics and pre-clinical in vivo efficacy that could be rationalised through a PK/PD relationship...
  5. ncbi Use of small-molecule crystal structures to address solubility in a novel series of G protein coupled receptor 119 agonists: optimization of a lead and in vivo evaluation
    James S Scott
    Cardiovascular and Gastrointestinal Innovative Medicines Unit, AstraZeneca, Mereside, Alderley Park, Macclesfield, Cheshire SK10 4TG, United Kingdom
    J Med Chem 55:5361-79. 2012
    ..The compound was shown to be effective in wild-type but not knockout animals, confirming that the biological effects were due to GPR119 agonism...
  6. ncbi Novel thienopyrrole glycogen phosphorylase inhibitors: synthesis, in vitro SAR and crystallographic studies
    Paul R O Whittamore
    AstraZeneca, Alderley Park, Macclesfield, Cheshire, SK10 4TG, UK
    Bioorg Med Chem Lett 16:5567-71. 2006
    ..Representative compounds have been shown to bind at the dimer interface site of the rabbit muscle enzyme by X-ray crystallography...
  7. ncbi Matched molecular pair analysis of activity and properties of glycogen phosphorylase inhibitors
    Alan M Birch
    AstraZeneca, Mereside, Alderley Park, Macclesfield, Cheshire SK10 4TG, UK
    Bioorg Med Chem Lett 19:850-3. 2009
    ..Matched molecular pair analysis has been used in design of inhibitors of glycogen phosphorylase...
  8. ncbi Rationally designing safer anilines: the challenging case of 4-aminobiphenyls
    Alan M Birch
    AstraZeneca Pharmaceuticals, Mereside, Alderley Park, Macclesfield, SK10 4TG, UK
    J Med Chem 55:3923-33. 2012
    ..The calculations provided SAR-like information that was able guide the design of further examples of 4-aminobiphenyls that are not active in the Ames test...